Meeting
2013 ASCO Annual Meeting
Phase II, randomized, double-blind placebo-controlled trial of nimotuzumab plus gemcitabine compared with gemcitabine alone in patients (pts) with advanced pancreatic cancer (PC).
Authors
Dirk Strumberg
Marienhospital Herne, Herne, Germany
Dirk Strumberg , Beate Schultheis , Matthias Philip Ebert , A. Kerkhoff , Ralf Dieter Hofheinz , Dirk M. Behringer , Wolfgang E. Schmidt , Erdem Goker , Sara De Dosso , Michael Kneba , Suayib Yalcin , Friedrich Overkamp , Frank Schlegel , M. Dommach , Robert Rohrberg , Tilman Steinmetz , Dirk Reuter , Ferdinand Bach
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Pancreatic Cancer
Clinical Trial Registration Number
NCT00561990
Citation
J Clin Oncol 31, 2013 (suppl; abstr 4009)
DOI
10.1200/jco.2013.31.15_suppl.4009
Abstract #
4009
Poster Bd #
1
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
Dual MEK/EGFR inhibition for advanced, chemotherapy-refractory pancreatic cancer: A multicenter phase II trial of selumetinib (AZD6244; ARRY-142886) plus erlotinib.
First Author: Andrew H. Ko
Poster
2011 ASCO Annual Meeting
Randomized phase II study of gemcitabine (G) plus anti-IGF-1R antibody MK-0646, G plus erlotinib (E) plus MK-0646 and G plus E for advanced pancreatic cancer.
First Author: M. M. Javle
Poster
2021 Gastrointestinal Cancers Symposium
Phase II randomized, double-blind study of mFOLFIRINOX plus ramucirumab versus mFOLFIRINOX plus placebo in advanced pancreatic cancer patients (HCRN GI14-198).
First Author: Walid Labib Shaib
Poster
2019 Gastrointestinal Cancers Symposium
FOLFIRINOX in pancreatic cancer patients age 75 years or older.
First Author: Jonathan Mizrahi